How vaccine is responsible to activate our immune system ?
Plz answer immediately
Answers
Answered by
1
Vaccine contain the antigen in its weak form that enters the body through vaccination and our body tend to form antibodies against it and save a memory of these antibodies for future use
Yelishi:
tnx
Pleasure is all mine
Answered by
1
.Today, owing to strict health and safety issues of vaccine manufacturing, vaccines must meet higher standards of safety and biochemical characterization than they did in the past.”
The biggest triumph in vaccination is the eradication of smallpox. Ironically, no methods to measure vaccine immunity were set in place. Protection and immunity was achieved without detailed analysis nor knowledge of cellular or humoral immunity induction. Today, owing to strict health and safety issues of vaccine manufacturing, vaccines must meet higher standards of safety and biochemical characterization than they did in the past. This has led to the production of highly purified vaccines, and the identification and isolation of the antigens responsible for protection. A vaccine cannot move forward without the demonstration of effective immunity induced by the regime. Moreover, contrary to the vaccination strategy that eradicated smallpox and other acute viral infections, several modern vaccines aim at the eradication of established chronic diseases such as chronic viral infections or cancer. As the pathogens or cancer antigens are generally intracellular, modern vaccines can rely less effectively on the neutralizing properties of antibody responses that cannot cross the cell membrane, and depend predominantly on T-cell-based recognition of affected cells for their elimination. Thus, new technologies have to be developed to measure vaccine immunity.
Are we going round and round in circles? Are we making it harder for ourselves? Is vaccine development getting too hard? Why do we have to demonstrate immunity, if we can show protection? No regulatory agency will take a vaccine forward that is not highly purified and can demonstrate immunity induction.
Several methods of measuring humoral and cellular immunity have been required to be developed to meet this criteria. Some methods include ELISA, cytotoxic T-lymphocyte (CTL) assay, CTL precursor frequency assay, T-cell proliferation assays, carboxyfluorescein diacetate succinimidyl ester assays, intracellular and extracellular cytokine production by cells in culture using either ELISA or multiplex and flow cytometry, polyfunctional T-cell assays, ELISpot and MHC class I/II tetramers. Thus, there is an enormous amount of information and reagents available for guiding vaccine and immunotherapeutics development.
This special issue on ‘Methods to measure vaccine immunity’ focuses on a number of recent and promising approaches used to measure immunity induced following vaccination. Topics included in this special focus issue are as follows:
Gene-expression profiling in vaccine therapy and immunotherapy for cancer [1]. The use of microarrays is described in order to understand the mechanism by which tumors are rejected;
Antibody-profiling technologies for studying humoral responses to infectious agents [2]. Protein microarrays are used to evaluate antibody responses to thousands of antigens at one time. The luciferase immunoprecipitation system overcomes some drawbacks of the conventional protein microarray assay. These new technologies offer a new tool for understanding humoral immunity induction to proteins;
Vaccine-induced antibody responses in patients with carcinoma [3]. A nice overview of current methods utilized for measuring antibody responses and for assessing their antitumor efficacy in the context of clinical trials;
Methods to measure T-cell responses [4]. A mini review on recent methods used to measure T-cell immunity, such as the use of CTL, CTL precursor frequency assays,
The biggest triumph in vaccination is the eradication of smallpox. Ironically, no methods to measure vaccine immunity were set in place. Protection and immunity was achieved without detailed analysis nor knowledge of cellular or humoral immunity induction. Today, owing to strict health and safety issues of vaccine manufacturing, vaccines must meet higher standards of safety and biochemical characterization than they did in the past. This has led to the production of highly purified vaccines, and the identification and isolation of the antigens responsible for protection. A vaccine cannot move forward without the demonstration of effective immunity induced by the regime. Moreover, contrary to the vaccination strategy that eradicated smallpox and other acute viral infections, several modern vaccines aim at the eradication of established chronic diseases such as chronic viral infections or cancer. As the pathogens or cancer antigens are generally intracellular, modern vaccines can rely less effectively on the neutralizing properties of antibody responses that cannot cross the cell membrane, and depend predominantly on T-cell-based recognition of affected cells for their elimination. Thus, new technologies have to be developed to measure vaccine immunity.
Are we going round and round in circles? Are we making it harder for ourselves? Is vaccine development getting too hard? Why do we have to demonstrate immunity, if we can show protection? No regulatory agency will take a vaccine forward that is not highly purified and can demonstrate immunity induction.
Several methods of measuring humoral and cellular immunity have been required to be developed to meet this criteria. Some methods include ELISA, cytotoxic T-lymphocyte (CTL) assay, CTL precursor frequency assay, T-cell proliferation assays, carboxyfluorescein diacetate succinimidyl ester assays, intracellular and extracellular cytokine production by cells in culture using either ELISA or multiplex and flow cytometry, polyfunctional T-cell assays, ELISpot and MHC class I/II tetramers. Thus, there is an enormous amount of information and reagents available for guiding vaccine and immunotherapeutics development.
This special issue on ‘Methods to measure vaccine immunity’ focuses on a number of recent and promising approaches used to measure immunity induced following vaccination. Topics included in this special focus issue are as follows:
Gene-expression profiling in vaccine therapy and immunotherapy for cancer [1]. The use of microarrays is described in order to understand the mechanism by which tumors are rejected;
Antibody-profiling technologies for studying humoral responses to infectious agents [2]. Protein microarrays are used to evaluate antibody responses to thousands of antigens at one time. The luciferase immunoprecipitation system overcomes some drawbacks of the conventional protein microarray assay. These new technologies offer a new tool for understanding humoral immunity induction to proteins;
Vaccine-induced antibody responses in patients with carcinoma [3]. A nice overview of current methods utilized for measuring antibody responses and for assessing their antitumor efficacy in the context of clinical trials;
Methods to measure T-cell responses [4]. A mini review on recent methods used to measure T-cell immunity, such as the use of CTL, CTL precursor frequency assays,
Copied from Internet
Similar questions